Potential therapeutic gene for the treatment of ischemic disease: Ad2/hypoxia-inducible factor-1α (HIF-1)/VP16 enhances B-type natriuretic peptide gene expression via a HIF-1-responsive element

Molecular Pharmacology

Volumn 69, Issue 6, 2006, Pages 1773-1778

  Wilhide, Michael E ^a   Jones, W Keith ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; DNA BINDING PROTEIN; ETOPOSIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CHIMERA; CONTROLLED STUDY; DIMERIZATION; DNA BINDING; DRUG RESEARCH; GENE EXPRESSION; GENE THERAPY; HEART MUSCLE CELL; HEART PROTECTION; HUMAN; HUMAN CELL; ISCHEMIA; ISCHEMIC HEART DISEASE; LIMB ISCHEMIA; NONHUMAN; PERIPHERAL ISCHEMIA; PRIORITY JOURNAL; REVASCULARIZATION; REVIEW; TREATMENT PLANNING; UNITED STATES;

ANOXIA; CORONARY DISEASE; GENE THERAPY; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MYOCYTES, CARDIAC; NATRIURETIC PEPTIDE, BRAIN; RECOMBINANT FUSION PROTEINS; RESPONSE ELEMENTS; TRANS-ACTIVATION (GENETICS);

EID: 33745181228     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.106.024968     Document Type: Review

References (47)

1. Bendermacher BL, Willigendael EM, Teijink JA, and Prins MH (2005) Medical management of peripheral arterial disease. J Thromb Haemost 3:1628-1637.
2. Cargill RI and Lipworth BJ (1995) Acute effects of ANP and BNP on hypoxic pulmonary vasoconstriction in humans. Br J Clin Pharmacol 40:585-590.
3. Chi NC and Karliner JS (2004) Molecular determinants of responses to myocardial ischemia/reperfusion injury: focus on hypoxia-inducible and heat shock factors. Cardiovasc Res 61:437-447.
4. D'Angio CT and Finkelstein JN (2000) Oxygen regulation of gene expression: a study in opposites. Mol Genet Metab 71:371-380.
5. Date T, Mochizuki S, Belanger AJ, Yamakawa M, Luo Z, Vincent KA, Cheng SH, Gregory RJ, and Jiang C (2005) Expression of constitutively stable hybrid hypoxia-inducible factor-1alpha protects cultured rat cardiomyocytes against simulated ischemia-reperfusion injury. Am J Physiol 288:C314-C320.
6. Dennis SC, Gevers W, and Opie LH (1991) Protons in ischemia: where do they come from; where do they go to? J Mol Cell Cardiol 23:1077-1086.
7. Freedman SB and Isner JM (2001) Therapeutic angiogenesis for ischemic cardiovascular disease. J Mol Cell Cardiol 33:379-393.
8. Gounis MJ, Spiga MG, Graham RM, Wilson A, Haliko S, Lieber BB, Wakhloo AK, and Webster KA (2005) Angiogenesis is confined to the transient period of VEGF expression that follows adenoviral gene delivery to ischemic muscle. Gene Ther 12:762-771.
9. Giaccia A, Siim B, and Johnson R (2003) HIF-1 as target for drug development. Nat Rev Drug Disc 2:803-811.
10. Heinl-Green A, Radke PW, Munkonge FM, Frass O, Zhu J, Vincent K, Geddes DM, and Alton EW (2005) The efficacy of a 'master switch gene' HIF-1alpha in a porcine model of chronic myocardial ischaemia. Eur Heart J 26:1327-1332.
11. Hochachka PW (1999) The metabolic implications of intracellular circulation. Proc Natl Acad Sci USA 96:12233-12239.
12. Holleyman CR and Larson DF (2001) Apoptosis in the ischemic reperfused myocardium. Perfusion 16:491-502.
13. Ikeda E (2005) Cellular responses to tissue hypoxia and its involvement in disease progression. Pathol Int 55:603-610.
14. Jiang BH, Rue E, Wang GL, Roe R, and Semenza GL (1996) Dimerization, DNA binding and transactivation properties of hypoxia-inducible factor-1. J Biol Chem 271:17771-17778.
15. Jiang C, Lu H, Vincent K, Shankara S, Belanger A, Cheng S, Akita G, Kelly R, Goldberg M, and Gregory R (2002) Gene expression profiles in human cardiac cells subjected to hypoxia or expressing a hybrid form of HIF-1α. Physiol Genomics 8:23-32.
16. Josko J and Mazurek M (2004) Transcription factors having impact on vascular endothelial growth factor (VEGF) gene expression in angiogenesis. Med Sci Monit 10:RA89-RA98.
17. Kastrup J, Jorgensen E, Ruck A, Tagil K, Glogar D, Ruzyllo W, Botker HE, Dudek D, Drvota V, Hesse B, et al. (2005) Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial. J Am Coll Cardiol 45:982-988.
18. Kawakami R, Saito Y, Kishimoto I, Harada M, Kuwahara K, Takahashi N, Nakagawa Y, Nakanishi M, Tanimoto K, Usami S, et al. (2004) Overexpression of brain natriuretic peptide facilitates neutrophil infiltration and cardiac matrix metalloproteinase-9 expression after acute myocardial infraction. Circulation 110:3306-3312.
19. Khan TA, Sellke FW, and Laham RJ (2003) Gene therapy progress and prospects: therapeutic angiogenesis for limb and myocardial ischemia. Gene Ther 10:285-291.
20. Kubasiak LA, Hernandez OM, Bishopric NH, and Webster KA (2002) Hypoxia and acidosis activate cardiac myocyte death through the Bcl-2 family protein BNIP3. Proc Natl Acad Sci USA 99:12825-12830.
21. LaPointe M (2005) Molecular regulation of the brain natriuretic peptide gene. Peptides 26:944-956.
22. Luo Y, Jiang C, Belanger A, Akita G, Wadsworth S, Gregory R, and Vincent K (2006) A constitutively active hypoxia-inducible factor-1α/VP16 hybrid factor activates expression of the human B-type natriuretic peptide gene. Mol Pharmacol 69:1953-1962.
23. Makino H, Ogihara T, and Morishita R (2005) Gene therapy for peripheral arterial disease. Nippon Rinsho 63 (Suppl 12):582-587.
24. Neely JR and Grotyohann LW (1984) Role of glycolytic products in damage to ischemic myocardium. Dissociation of adenosine triphosphate levels and recovery of function of reperfused ischemic hearts. Circ Res 55:816-824.
25. Nishikimi T, Maeda N, and Matsuoka H (2006) The role of natriuretic peptides in cardioprotection. Cardiovasc Res 69:318-328.
26. Pajusola K, Kunnapuu J, Vuorikoski S, Soronen J, Andre H, Pereira T, Korpisalo P, Yla-Herttuala S, Poellinger L, and Alitalo K (2005) Stabilized HIF-1alpha is superior to VEGF for angiogenesis in skeletal muscle via adeno-associated virus gene transfer. FASEB J 19:1365-1367.
27. Patel H, Kimura H, Weiss C, Semenza G, and Hofmann L (2005) Constitutively active HIF-1α improves perfusion and arterial remodeling in an endovascular model of limb ischemia. Cardiovasc Res 68:144-154.
28. Paul SA, Simons JW, and Mabjeesh NJ (2004) HIF at the crossroads between ischemia and carcinogenesis. J Cell Physiol 200:20-30.
29. Pugh CW and Ratcliffe PJ (2003) Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 9:677-684.
30. Rebar EJ (2004) Development of pro-angiogenic engineered transcription factors for the treatment of cardiovascular disease. Expert Opin Investig Drugs 13:829-839.
31. Ruck A, Gustafsson T, Norrbom J, Nowak J, Kallner G, Soderberg M, Sylven C, and Drvota V (2004) ANP and BNP but not VEGF are regionally overexpressed in ischemic human myocardium. Biochem Biophys Res Commun 322:287-291.
32. Salceda S and Caro J (1997) Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 272:22642-22647.
33. Shah PB and Losordo DW (2005) Non-viral vectors for gene therapy: clinical trials in cardiovascular disease. Adv Genet 54:339-361.
34. Segerer A, Stetter KO, and Klink F (1985) Two contrary modes of chemolithotrophy in the same archaebacterium. Nature (Lond) 313:787-789.
35. Serruys PW, Heyndrickx GR, Patel J, Cummins PA, Kleijne JA, and Clowes AW (2003) Effect of an anti-PDGF-beta-receptor-blocking antibody on restenosis in patients undergoing elective stent placement. Int J Cardiovasc Intervent 5:214-222.
36. Shyu K, Wang MT, Wang BW, Chang CC, Leu JG, Kuan P, and Chang H (2002) Intramyocardial injection of naked DNA encoding HIF-1α/VP16 hybrid to enhance angiogenesis in an acute myocardial infraction model in the rat. Cardiovasc Res 54:576-583.
37. Takano H, Zou Y, Hasegawa H, Akazawa H, Nagai T, and Komuro I (2003) Oxidative stress-induced signal transduction pathways in cardiac myocytes: involvement of ROS in heart diseases. Antioxid Redox Signal 5:789-794.
38. Tamura N, Ogawa Y, Chusho H, Nakamura K, Nakao K, Suda M, Kasahara M, Hashimoto R, Katsuura G, Mukoyama M, et al. (2000) Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci USA 97:4239-4244.
39. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, Zheng ZJ, Flegal K, O'Donnell C, Kittner S, et al. (2006) American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics. Committee and Stroke Statistics Subcommittee. Circulation 113:e85-e151.
40. van der Zander K, Houben AJ, Kroon AA, and de Leeuw PW (1999) Effects of brain natriuretic peptide on forearm vasculature: comparison with atrial natriuretic peptide. Cardiovasc Res 44:595-600.
41. Vincent K, Shyu KG, Luo Y, Magner M, Tio R, Jiang C, Goldberg M, Akita G, Gregory R, and Isner J (2000) Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1α/VP16 hybrid transcriptional factor. Circulation 102:2255-2261.
42. Vincent KA, Feron O, and Kelly RA (2002) Harnessing the response to tissue hypoxia: HIF-1 alpha and therapeutic angiogenesis. Trends Cardiovasc Med 12:362-367.
43. Webster KA, Discher DJ, and Bishopric NH (1993) Induction and nuclear accumulation of fos and jun proto-oncogenes in hypoxic cardiac myocytes. J Biol Chem 268:16852-16858.
44. Webster KA, Discher DJ, Hernandez OM, Yamashita K, and Bishopric NH (2000) A glycolytic pathway to apoptosis of hypoxic cardiac myocytes. Molecular pathways of increased acid production. Adv Exp Med Biol 475:161-175.
45. Webster KA (2003) Evolution of the coordinate regulation of glycolytic enzyme genes by hypoxia. J Exp Biol 206:2911-2922.
46. Zagorska A and Dulak J (2004) HIF-1: the knowns and unknowns of hypoxia sensing. Acta Biochimica Polonica 51:563-585.
47. Zhao ZQ (2004) Oxidative stress-elicited myocardial apoptosis during reperfusion. Curr Opin Pharmacol 4:159-165.